Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel cancer therapy that could offer a more targeted approach for patients with limited treatment options. In a recent interview on the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed discussed the company's lead drug candidate, ONC010, and its unique strategy for attacking cancer cells.
ONC010 targets polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme that helps cancer cells survive damage from chemotherapy and radiation. By inhibiting PNKP, the drug aims to overwhelm cancer cells' ability to repair their DNA, leading to cell death. What sets ONC010 apart is its dual selectivity mechanisms. First, it exploits synthetic lethality, meaning it is designed to be lethal primarily to cancer cells that have lost the tumor suppressor PTEN or the signaling protein SHP-1, while sparing healthy cells. Second, a nanoparticle delivery system is intended to concentrate the drug within tumor tissue, further reducing systemic toxicity.
Dr. Mohamed pointed to preclinical research conducted at the University of Alberta, where the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity. In those studies, the drug was tolerated at tested doses and prolonged survival relative to controls. These findings support the company's plans to launch a first-in-human clinical program for ONC010.
Onco-Innovations, a Canadian-based oncology company, holds an exclusive worldwide license to patented technology for therapeutic inhibition of PNKP, a novel clinical target in the DNA damage response pathway. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
This development matters because PNKP inhibition represents a new frontier in precision oncology. If ONC010 succeeds in clinical trials, it could provide a much-needed option for patients whose tumors have become resistant to existing therapies due to PTEN or SHP-1 loss, which occurs in many breast, prostate, and blood cancers. The dual-selectivity approach may also reduce side effects compared to traditional chemotherapies, improving quality of life during treatment.
For investors, Onco-Innovations' progress is noteworthy. The company's shares trade on multiple exchanges, and its novel technology could attract partnership or licensing interest from larger pharmaceutical firms. However, as with any early-stage biotech, clinical trial risks remain. The upcoming first-in-human study will be a critical milestone to watch.
To view the full press release, visit https://ibn.fm/XgpMR. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. For more information about BioMedWire, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website: https://www.BioMedWire.com/Disclaimer.
